ARTICLE / CLIENT ALERT
California AB 3129 Targets the Health Facility Transactions Approval Process
February 23, 2024
Read time: 8 min
On February 16, 2024, Assemblymember Jim Wood introduced Assembly Bill (AB) 3129, which targets healthcare consolidation involving private equity groups and hedge funds. The bill, if enacted, would require private equity groups and hedge funds to receive consent from the attorney general prior to acquiring or affiliating with healthcare facilities or provider groups. The bill would also prohibit private equity groups or hedge funds from entering into certain management services arrangements with physicians or psychiatry practices. The bill is slated to be heard in committee on March 18, 2024.
Background
California law currently requires nonprofit corporations operating or controlling certain health facilities to provide written notice to, and obtain consent of, the attorney general prior to entering into certain asset sales or change of control transactions. Additionally, California Senate Bill 184, which will take effect April 1, 2024, imposes a 90-day notice requirement to California’s Office of Health Care Affordability on healthcare entities for transactions involving the sale or transfer of control of a material amount of assets or operations. AB 3129 represents an extension and expansion of such requirements but applies solely to private equity groups and hedge funds affiliating with healthcare facilities and provider groups.
AB 3129 Provisions
Notice Requirement
AB 3129 implements a 90-day prior notice requirement for any changes in control or acquisitions between private equity groups or hedge funds and a healthcare facility or provider group. The notice must contain sufficient information for the attorney general to determine whether the proposed transaction presents any anticompetitive effects or adversely affects the access or availability of healthcare services. The attorney general may extend the 90-day period by 45 days if it determines that additional information is necessary, the transaction is subsequently modified or the transaction involves a multifacility or multi-provider health system serving multiple communities. The attorney general may extend its review by 14 more days if it decides to hold a public meeting on the transaction.
Consent Requirement
In addition to the notice requirement, the attorney general’s consent would be required for proposed transactions between a private equity group or hedge fund and a healthcare facility or provider group, except for certain nonphysician transactions.
The attorney general would be authorized to grant, deny or impose conditions on the transaction if the transaction would have a “substantial likelihood of anticompetitive effects” or may create “a significant effect on the access or availability of health care services to the affected community.” In making the determination, the attorney general would apply the public interest standard, which looks to the “interests of the public in protecting competitive and accessible health care markets for prices, quality, choice, accessibility, and availability of all health care services for local communities, regions, or the state as a whole.”
Waiver
The attorney general may waive the notice and consent requirements, within 60 days of receiving a waiver request, where all of the following conditions apply:
- The party makes a written waiver request including all information that the attorney general deems necessary.
- The party’s operating costs have exceeded its operating revenue in the relevant market for three or more years and the party cannot meet its debts.
- The party is at grave risk of immediate business failure and can demonstrate a substantial likelihood of chapter 11 bankruptcy absent the waiver.
- The party would be substantially unable to reorganize under a chapter 11 bankruptcy.
- The acquisition or change of control will ensure continued healthcare access in the relevant markets.
- The party has made commercially reasonable best efforts in good faith to elicit reasonable alternative offers that would pose a less severe danger to competition than the current transaction.
Reconsideration and Review
Within 10 days of the attorney general’s notice of decision, the parties may avail themselves of a reconsideration process to modify, amend or revoke the decision. The parties must provide some basis in new or different facts, circumstances or law and the attorney general must provide a reconsideration decision within 30 days.
Upon an unfavorable reconsideration decision, the parties may seek judicial review of the final determination. The superior court shall respond to such a request within 180 days of receipt of the petition.
Prohibitions on Certain Arrangements
AB 3129 would also prohibit private equity groups and hedge funds from controlling or directing physician or psychiatric practices. Specifically, the bill would prohibit, among other actions, private equity groups and hedge funds from influencing or entering into contracts on behalf of the practice or providers with any third party, influencing or setting rates for the practice or providers with any third party, or influencing or setting patient admission, referral or availability policies.
The bill would also prohibit the physician or psychiatric practices from entering into agreements with an entity controlled in part or in whole, directly or indirectly, by private equity groups and hedge funds under which the latter manages any of the affairs of the former in exchange for a fee (though it does not bar revenue sharing between the practice and private equity group or hedge fund).
The bill also prohibits the inclusion of any noncompetition provisions or non-disparagement provisions as it relates to quality of care, utilization of care, ethical or professional challenges, or revenue increasing strategies in contracts between physician or psychiatric practices and private equity groups or hedge funds.
Key Definitions
- “Acquisition” means any direct or indirect purchase, including (but not limited to) a “lease, transfer, exchange, option, receipt of a conveyance, creation of a joint venture, or any other manner of purchase” of a “material amount of the assets or operations” of a healthcare facility or provider.
- “Change of control” is found where the arrangement effects a change in governance or sharing of control over healthcare services or where the private equity group or hedge fund otherwise acquires direct or indirect control over the operations of the healthcare facility.
- “Healthcare facility” means any “facility, nonprofit or for-profit corporation, institution, clinic, place, or building where health-related physician, surgery, or laboratory services are provided.”
- “Hedge fund” means “a pool of funds by investors, including a pool of funds managed or controlled by private limited partnerships, if those investors or the management of that pool or private limited partnership employ investment strategies of any kind to earn a return on that pool of funds.”
- “Nonphysician providers” means a group of two or more individuals licensed under Division 2 of the California Business and Professions Code who do not “provide health-related physician, surgery, or laboratory services to consumers.” This definition would include a wide variety of ancillary providers, such as chiropractors, physical therapists, optometrists, etc.
- “Private equity group” means “an investor or group of investors who engage in the raising or returning of capital and who invests, develops, or disposes of specified assets.”
- “Provider” means a group of two to nine individuals, except provider groups, that “provide[] health-related physician, psychiatric, surgery, or laboratory services to consumers.”
- “Provider group” means a group of 10 or more providers that provide “health-related physician, psychiatric, surgery, or laboratory services to consumers” or a group of providers that generate an annual revenue of $10 million or more.
Of note, the above definitions do not apply to transactions entered into before January 1, 2025, including subsequent renewals, so long as there is not a “material change” in the corporate relationship of the transacting parties on or after January 1, 2025.
Analysis
AB 3129 represents a continuation of the nationwide trend toward increased regulation over healthcare transactions. If passed, the bill would impose significant pre-closing requirements on private equity groups and hedge funds seeking to do business involving healthcare facilities or provider groups in the state of California.
The bill may be heard in committee as early as March 18, 2024. McDermott will continue to monitor the bill’s progression through the state legislature and provide updates.
Key Takeaways
- Private equity groups and hedge funds would be required to submit a 90-day pre-closing written notice of any changes in control or acquisitions of healthcare facilities or provider groups.
- The attorney general would be able to grant, deny or impose conditions on such proposals.
- Any party would be able to request a reconsideration of the attorney general’s decision within 10 days of notice and, subsequently, may request a judicial review of the final determination on the reconsideration.
- Proposals involving nonphysician providers generating an annual revenue below $4 million or involving fewer than 10 providers or a group of providers generating an annual revenue below $10 million would not require consent of the attorney general but notice would still be required.
- AB 3129 would also prohibit many common management or administrative service arrangements between entities controlled directly or indirectly by private equity groups or hedge funds with physician or psychiatric practices.

Ensuring Nondiscrimination in Patient Visitations
ARTICLE / CLIENT ALERT
Ensuring Nondiscrimination in Patient Visitations
February 22, 2024
Read time: 6 min
Reflecting on lessons learned and complaints received during the COVID-19 pandemic, the US Department of Health and Human Services (HHS) Office for Civil Rights (OCR) released detailed frequently asked questions (FAQs) regarding patient visitation rights in hospitals, critical-care hospitals and long-term care facilities. These FAQs emphasize that any visitation restrictions should be based on clinical reasons rather than discriminatory reasons.
As we have previously reported, the Biden administration has maintained a concerted focus on addressing discrimination in the delivery and receipt of healthcare. In 2022, the Biden administration established the Interagency Policy Committee on Antisemitism, Islamophobia, and Related Forms of Bias and Discrimination, which, among other things, instructed HHS to produce reference materials for healthcare providers on discrimination in the delivery of patient care on the bases of race, religion, ethnicity and national origin and to include in those materials specific examples of antisemitic, Islamophobic, and related forms of bias and discrimination in healthcare settings.
All facilities, including hospitals, critical-access hospitals and long-term care facilities subject to patient visitation regulations, are prohibited from restricting, limiting or otherwise denying visitation privileges based on race, color, national origin, religion, sex, gender identity, sexual orientation, or disability and are required to have written visitation policies, procedures and practices regarding such prohibitions.
As care facilities of all types struggled to balance infection-control obligations with patient visitation rights during the COVID-19 pandemic, OCR received countless complaints about discriminatory visitation policies. Aggregating these complaints and other lessons learned from the pandemic, OCR released guidance in the form of in-depth FAQs to ensure that hospitals and long-term care facilities, critical-access hospitals, and any other entity that receives federal financial assistance from HHS are aware of their obligations to patients and residents.
The FAQs highlighted some important reminders, including:
- Patients and residents have the right to receive any visitor they designate, including a spouse, domestic partner, family member, friend or faith leaders of their choosing. This is important because patients receiving care often feel isolated or distressed while in a care facility but find comfort and support through visitation from family, caregivers, friends, clergy and others.
- Persons providing support to individuals with a disability because of said disability should be allowed irrespective of a patient’s or resident’s right to receive visitors or a healthcare entity’s infection-control requirements.
- Patient visitation rights apply to all patients, not just Medicare or Medicaid beneficiaries, and to all entities that receive federal financial assistance from HHS.
- All facilities are required to inform patients of their visitation rights. Facilities must also have written policies and procedures relating to patient visitation rights that include (i) any clinically necessary or reasonable restriction or limitation that the entity may need to place on the visitation rights of patients, and (ii) the reasons for the clinical restriction or limitation.
- Facilities may limit patient visitation as long as (i) the restrictions are clinically necessary or otherwise reasonable, (ii) they inform the patients of the policies and procedures in advance of the provision or discontinuation of care, (iii) the policies are in writing, and (iv) restrictions may not be based on race, color, national origin, religion, sex, gender identity, sexual orientation or disability. We note that under federal civil rights laws, facilities may also restrict visitation for safety reasons so long as they are based on objective risks (e.g., limiting the number of visitors allowed inside the building or a room at a given time).
- Facilities may limit visitation during infectious-disease outbreaks if they determine that the limitation is clinically necessary or otherwise reasonable and do not impose restrictions based on discriminatory grounds. Even during an outbreak or public-health emergency, facilities should maintain visitation policies or procedures and notify patients or residents as required under applicable regulations.
- A policy or procedure is discriminatory if (i) it prohibits certain visitors or (ii) requires additional screening for some and not others. This may include preventing families from bringing kosher or halal food to a patient while allowing other visitors to deliver non-religious food items.
- If a policy allows for visitors, it must also allow for visitation with clergy, ministers, chaplains or other faith leaders, even if the facility has a chaplaincy program.
- Facilities generally may not base visitation policies on assumptions or stereotypes regarding the likelihood of transmission of a communicable disease within certain communities. That said, during the COVID-19 pandemic, hospitals were allowed to limit visitation in some high-spreading communities based on objective factors such as prevalence of the disease. These restrictions were permissible as long as they were related to infection control needs rather than discriminatory factors and were applied universally to all patients or residents.
- When receiving care in a long-term care facility, a resident must be allowed access to immediate family members, the individual’s physician, and certain other individuals, such as state ombudspersons, so long as such access does not interfere with the rights of other residents.
- A facility may restrict how a patient or resident interacts with a visitor only if it is clinically necessary and reasonably restrictive, but it may not limit or deny visitation because of (For example, it was permissible to require visitors to wear protective gear during the COVID-19 pandemic).
- Covered entities must employ and abide by the same Centers for Medicare & Medicaid Services (CMS) regulatory requirements for virtual visitations that they follow for in-person visits. It is important that facilities ensure that any restriction on devices used to facilitate patient visitation do not discriminate based on religion. Further, long-term care facilities must provide alternative communication methods following the request for communication in lieu of an in-person visit, such as by phone or other technology.
- All complaints may be filed via the OCR complaint portal.
Key Takeaways and Considerations
All healthcare entities should remember that patients and residents have a general right to receive the visitors of their choosing, including religious leaders. Going forward, entities will be required to balance the medical need to restrict visitors with patients’ rights. Where questions arise, entities should take a position of neutrality as to who may visit.
If an entity insists that there is a justified reason for denying a patient’s visitation rights, we recommend that the decision-making process include robust and complete documentation of the situation and the nondiscriminatory reasons for the prohibition. Further, and to ensure consistency, facilities should focus on providing staff with training on policies and procedures relating to visitation.

California Imposes New Workplace Violence Prevention Mandate
ARTICLE / REPORT
California Imposes New Workplace Violence Prevention Mandate
February 22, 2024
Read time: 2 min
On September 30, 2023, California Governor Gavin Newsom signed SB 553 into law, creating a new layer to California employers’ existing injury and illness prevention programs (IIPP). Under SB 553, employers are required to implement a workplace violence prevention plan (WVPP) no later than July 1, 2024, to provide training to employees regarding the WVPP and to keep records of workplace violence incidents. As of January 1, 2025, the law also expands employers’ and employee representatives’ rights to obtain restraining orders on behalf of employees affected by threats of workplace violence.

Mixed beverage definition gaining traction in Indiana
ARTICLE
Mixed beverage definition gaining traction in Indiana
Feb 22, 2024
Read time: 2 min
Indiana is one step closer to passing legislation that would allow popular liquor-based, ready-to-drink products to be defined as “mixed beverages” that currently fall under the definition of liquor in the state.
An Indiana House of Representatives committee advanced House Bill 1025 earlier this month. The bill would add a new section to Indiana Code 7.1-1-3-26.2 that would read:
“Mixed beverage” means a prepared cordial, cocktail, or highball that is in a can or container that holds not more than twenty-four (24) ounces of the beverage and is a mixture of: (1) whiskey, neutral spirits, brandy, gin, or another distilled 8 spirit; and (2) carbonated or plain water, pure juice from a flower or plant, or other flavoring materials; that is suitable for immediate consumption and contains not less 12 than five-tenths percent(0.5%) of alcohol by volume and not more 13 than fifteen percent (15%) of alcohol by volume.”
The definition change would also allow for beer wholesalers, who also hold a wine license, to sell mixed beverages in Indiana. As such, there are many opposing the bill. We will continue to update the blog when any changes are made in the state.

SEC Targets Certain Proprietary Trading Firms and Private Funds With Expanded “Dealer” Definition
ARTICLE / CLIENT ALERT / US POLICY
SEC Targets Certain Proprietary Trading Firms and Private Funds With Expanded “Dealer” Definition
February 21, 2024
Read time: 19 min
Executive Summary
On Feb. 6, 2024, the US Securities and Exchange Commission (“SEC” or “Commission”) adopted new Rules 3a5‑4 and 3a44‑2 (together, “Final Rules”)[1] under the Exchange Act to further define what it means to be “engaged in the business” of buying and selling securities for one’s own account and, as such, required to register with the SEC as a “dealer” or “government securities dealer,” as applicable (collectively, a “Dealer”). The Final Rules establish two non-rebuttable qualitative standards — one that targets the regularity of a market participant’s expressions of trading interest (“Expressing Trading Interest” factor, as further defined below) and another that targets a market participant’s primary source of revenue (“Primary Revenue” factor, as further defined below) — to determine if a market participant is required to register as Dealer. While the Final Rules have been significantly scaled back from the SEC’s initial proposal (“Proposal”),[2] based on the qualitative standards set forth in the Final Rules, certain private investment funds and their advisers may be required to register as Dealers.
The Commission declined to adopt the two most controversial provisions of the Proposal. The first was an additional qualitative standard that would have required any persons who “routinely [makes] roughly comparable purchases and sales of the same or substantially similar securities (or government securities) in one day” to register as a Dealer.[3] The second was a quantitative standard that would have required any person who, in four of the last six calendar months, bought or sold over $25 billion in US Treasuries to register as a “government securities dealer.” However, in what appears to be a significant expansion from the Proposal, the Adopting Release notes market participants do not need to express trading interest continuously nor simultaneously be on both sides of the market to be captured by the Expressing Trading Interest test.
Additionally, the SEC declined to adopt the broad definition of “own account” included in the Proposal, which would have required that investment advisers aggregate activity across private funds and accounts managed by the adviser. Instead, the SEC adopted a definition of “own account” that focuses on the entity engaged in the dealer activity along with an anti-evasion prohibition designed to restrict circumvention of the Final Rules.
Final Rules
As adopted, the Final Rules require that, subject to limited exceptions, any person who “engages in a regular pattern of buying and selling securities [or government securities] for their own account that has the effect of providing liquidity”[4] by engaging in the below activities must register as a Dealer:
- Regularly express trading interest that is at or near the best available prices on both sides of the market for the same security and that is communicated and represented in a way that makes it accessible to other market participants (“Expressing Trading Interest” test);[5] or
- Earning revenue primarily from capturing bid-ask spreads, by buying at the bid and selling at the offer, or from capturing any incentives offered by trading venues to liquidity-supplying trading interest (“Primary Revenue” test).[6]
While the SEC did not adopt the proposed “roughly comparable purchases and sales” qualitative standard, the SEC cautioned that such activity may still be “de facto market making under the [adopted] two qualitative tests or dealer activity under otherwise applicable precedent.”[7] Further comments in the Adopting Release and a lack of clarity on key terms may permit broad interpretations of the two adopted qualitative tests to cover some of the activities previously captured by the “roughly comparable purchases and sales” test. The Commission also emphasized that the two adopted standards are non-exclusive, meaning that market participants must continue to assess their activities against existing SEC guidance and court precedent. This may be disappointing for market participants looking for additional clarity in light of recent court cases.[8]
Expressing Trading Interest Test
Under the Expressing Trading Interest test, a person “regularly expressing trading interest that is at or near the best available prices on both sides of the market for the same security and that is communicated and represented in a way that makes it accessible to other market participants” is engaged in buying and selling securities for its own account “as a part of a regular business.”[9] While the Commission stated it adopted this test largely as proposed, it made two significant textual changes. The first was to add the phrase “for the same security” to explicitly provide in the Final Rules that the expressions of trading interest must be for the same security. The second change replaced the term “routinely” from the Proposal with “regularly.” Additionally, the Commission provided guidance on a number of terms used under the Expressing Trading Interest. This guidance indicates that the SEC may take an expansive view of what activity is captured by the test.
“On Both Sides of the Market”
While the Final Rules clarify that the Expressing Trading Interest test requires a person’s trading interest to be “on both sides of the market for the same security,” the Commission declined to require that expressions of trading interest be simultaneous or provide a time horizon over which to evaluate single-sided expressions of trading interest. The Commission explained that “participants will need to assess the totality of their trading activity to determine if they are expressing trading interests on both sides of the market for the same security sufficiently close in time to have the effect of providing liquidity in the same security to other market participants,”[10] including in determining whether their quoting activity meets the Final Rules’ “regularly expressing” standard.
“Regularly Expressing”
As proposed, the Expressing Trading Interest test would have required a person who “routinely” expresses trading interest at or near the best available prices on both sides to register as a Dealer. While the SEC noted that the term “routine” was “intended to capture significant liquidity providers who express trading interests at a high enough frequency to play a significant role in price discovery and the provision of market liquidity, even if their liquidity provision may not be continuous like that of some traditional dealers,”[11] commenters expressed concern due to a lack of clarity and ambiguous nature of the term. Rather than directly addressing these concerns through a formal definition or clear guidance, the SEC replaced the term “routinely” with “regularly,” indicating the change was intended to mirror the statutory text.[12] Notwithstanding the SEC’s note regarding its purpose, this change may result in additional activity being captured by the Final Rules. For instance, while the term “routine” indicates activity that is common and expected, the term “regular” could include activities that, while not routine, simply occur with some frequency (contrast one’s morning “routine” with “regularly” traveling for work).
The term “regularly” in the final rules will apply to a person’s expression of trading interest both “within a trading day and over time.”[13] This requirement is intended to distinguish persons engaged in isolated or sporadic expressions of trading interest from persons whose regularity of expression of trading interest demonstrates that they are acting as Dealers. The Commission was clear, however, that a person does not need to be “continuously expressing trading interest” to be engaging in a “regular” business; rather, whether a person’s activity is “regular” will depend on the liquidity and depth of the relevant market for the security.[14]
For example, while expressing trading interest “as part of an investment strategy on a one-off basis,” in a liquid market would not meet the requirements of the Expressing Trading Interest test,[15] in less liquid markets (e.g., where it is more difficult to execute orders or large orders can significantly impact the price of the security), “regular” would include the “possibility of more interruptions or wider spreads for the best available prices.”[16]
“At or Near the Best Available Prices”
While the Expressing Trading Interest test requires that quoting activity be “at or near the best available prices on both sides of the market,” the Final Rules and Adopting Release provide little guidance on this standard. Notably, statements by the SEC during the open meeting to consider the Proposal suggested that the SEC would look to the relevant facts and circumstances to determine if expressions of trading interest are at or near the best available prices.[17]
Further, in the Adopting Release, the Commission explained that, in determining whether trading interest was expressed “at or near” the best available price, market participants should look to information typically used to make bids and offers, including “recently completed purchases and sales and the totality of indications of willingness to buy or sell at specified prices.”[18]
The SEC did, however, clarify that a market participant seeking price information by requesting quotes on a security, without including prices, on both sides of the market would generally not satisfy this qualitative test because that trading interest, absent more, would not be “at or near the best available price.”[19] Additionally, the Commission acknowledged that an adviser’s fiduciary duty may require it to submit “trading interests” throughout a trading day and explained that the Final Rules have been modified such that the trading interest expressed by an investment adviser for purposes of its fiduciary duty to its clients and their its accounts would not be activity captured by the Expressing Trading Interest test, unless the investment adviser itself is the account holder or the account is held for the benefit of the investment adviser.
“Trading Interest”
The term “trading interest” means: (i) an “order” as the term is defined in Rule 3b-16(c)[20] or (ii) any non-firm indication of a willingness to buy or sell a security that identifies the security and at least one of the following: quantity, direction (buy or sell) or price.[21] The SEC indicated that the second prong of this definition is intended to account for “the various and evolving ways in which buyers and sellers of securities are brought together.”[22]
“Accessible to Other Market Participants”
The phrase “accessible to other market participants” reflects the requirement that a person’s trading interest must be expressed to more than one market participant to be captured under the test.[23] The SEC notes, however, that the particular method of communication or representation is not controlling and that multiple individual communications could qualify if they are communicated to more than one market participant.[24]
Primary Revenue Factor
The Commission adopted, as proposed, the Primary Revenue test, which requires a person to register as a dealer or government securities dealer if that person is “earning revenue primarily from capturing bid-ask spreads, by buying at the bid and selling at the offer, or from capturing any incentives offered by trading venues to liquidity-supplying trading interest.”[25]
Revenue
While the SEC provided guidance indicating that generating the majority of one’s revenue from price appreciation, rather than capturing the bid-ask spread, would indicate somebody was not engaged in dealer activity, the Commission failed to clarify how “revenue” should be assessed under the Final Rules or adopt a “profitability” standard in its place (as suggested by commenters).[26] However, the Commission made it clear that a person’s trading strategies would not need to be profitable to bring them within the rule.[27]
Trading Venue
The term “trading venue” is intended to capture the full variety of venues on which market participants engage in liquidity-providing dealer activity, both today and as they evolve.[28] The Commission explained that the particular venue matters less than the fact that a market participant provides liquidity on it.[29]
Scope
The Adopting Release notes that the effect of a person’s trading activity, rather than its stated purpose, controls in determining whether the Primary Revenue test has been met. Accordingly, cash management strategies involving government securities could inadvertently trigger the Primary Revenue test.[30]
Definition of “Own Account” & Aggregation
The Proposal would have defined the term “own account” to include both an account held by or for the benefit of such person and any account over which “that person exercises control or with whom that person is under common control.” This definition would have incorporated the definition of “control” from Exchange Act Rule 13h-1.
Additionally, the Proposal included the concept of a “parallel account structure,” which would have required separate legal entities not under common control to aggregate their activity where “one or more private funds …, accounts, or other pools of assets … managed by the same investment adviser pursue substantially the same investment objective and strategy and invest side-by-side in substantially the same positions as another parallel fund or parallel managed account.”[31]
As adopted, the definition of “own account” does not include any account over which “that person exercises control or with whom that person is under common control.”[32] Additionally, the Final Rules removed the concept of a “parallel account structure.” Rather, the Commission notes in the Adopting Release that it has elected to focus on activity on an entity-by-entity basis rather than aggregating accounts across entities based on control or commonality of investment objective and strategy.[33] Accordingly, the adopted definition of “own account” no longer requires aggregating activity across accounts that constitute a “parallel account structure and is limited to any account: (i) held in the name of that person or (ii) held for the benefit of that person.”[34]
Anti-Evasion
Rather than adopt the “control” or “parallel account structure” concepts, the Final Rules adopted an “anti-evasion” provision. This provision prohibits evading the Final Rules’ registration requirements by either: (i) engaging in activities indirectly that would satisfy the Expressing Trading Interest or Primary Revenue Factors or (ii) disaggregating accounts.[35]
The Commission makes it clear that anti-evasion provision is intended to capture persons dividing or structuring their activity to evade the application of the Final Rules and notes that potentially evasive activity includes, but is not limited to:[36]
- Coordinating and integrating trading across commonly controlled legal entities such that no entity meets the qualitative standards;
- Using two legal entities to separately purchase and sell securities; and
- Using several legal entities to purchase and sell securities but rotating the activity across the entity in a way that none of the entities trades frequently enough to satisfy the “regular” test under either factor.
In determining whether or not a person is evading the dealer registration requirements, the Commission may consider whether:[37]
- There are information barriers to prevent sharing of information or sufficiently segregated trading,
- There are overlapping personnel across accounts or entities,
- There are separate account statements for each account, or
- There is a business purposes that demonstrates that there is no coordinated buying and selling between accounts or entities.
Notably, the Commission provided that it would generally consider management by an adviser of managed accounts that are separately owned, but follow substantially the same investment objectives and strategies, to be ordinary course business activities and thus the Commission would not impute the trading in the clients’ accounts to the adviser’s own account, absent an intent to evade the dealer registration requirements.[38] Notwithstanding this exclusion, it is important to recognize that whether a person has violated the anti-evasion provision will depend on an evaluation of the totality of the facts and circumstances.
No Presumption
The Final Rules include a “no presumption” provision, stating that no presumption shall arise that a person is not a Dealer solely because such person’s activities are not captured by the adopted tests. Accordingly, the SEC could still determine that a market participant that does not trigger either of the qualitative standards is still a Dealer under applicable precedent.
Exclusions
The Proposal included an exclusion for registered investment companies and persons with less than $50 million of total assets.
A number of commenters requested additional exclusions, including exclusions for registered investment advisers and private funds. While the Commission declined to exclude investment advisers and private funds, the Final Rules expand the scope of excluded entities to add certain “Official Sector” entities[39] to the types of entities excluded from the Proposal (i.e., a person with less than $50 million of total assets and registered investment companies).[40]
The Commission also declined to exclude crypto asset securities from the Final Rules, noting that whether or not an entity is a Dealer depends on the securities trading activities undertaken by a firm, not the type of securities being traded.[41]
Potential Impact
As part of its economic analysis, the SEC identified certain market participants that it determined might be captured by the Final Rules. In determining who would be impacted, the Commission looked at data from FINRA’s Trade Reporting and Compliance Engine (TRACE) and Form PF.
Using TRACE data for US Treasury securities, the SEC identified firms that appeared to meet the Primary Revenue Factor by earning revenue from capturing bid-ask spreads in the market for US Treasury securities. As part of this exercise, the SEC noted that unregistered “principal trading firms” (or PTFs) were most likely to be impacted, noting their de facto role as market makers in the US Treasuries markets. Based on its analysis of TRACE data, the SEC approximated that 13-22 PTFs and four (4) private funds may be within scope of the rule.[42] The SEC was unable to estimate the number of entities that appear to meet the Expressing Trading Interest Factor because the Commission does not have sufficient data on quoting activities.
Outside of the market for Treasury securities, the SEC’s economic analysis relied on Form PF disclosures regarding private funds’ use of high frequency trading strategies. While the SEC acknowledged that it was unable to determine whether the self-reported HFT activities would satisfy the Expressing Trading Interest or Primary Revenue tests, it concluded that the funds most likely to be within the scope of the Final Rules were those funds with a higher percentage of their net asset value (“NAV”) dedicated to HFT strategies. Accordingly, the SEC identified as likely to meet the definition of Dealer under the Final Rules twelve (12) private funds that reported at least 10 percent of their NAV as associated with HFT strategies. For clarity, this is in addition to the four (4) private funds identified through TRACE data for US Treasury securities.
Enforcement Implications for Unregistered Dealer Activity
Notably, the SEC recognized that its approach in estimating the number of potentially impacted PTFs and private funds is imperfect as the estimate is based largely on what data was available to the SEC rather than clear indicators of potential dealer activity. While the Commission’s estimates are imperfect, its approach may help identify firms that are likely to be targeted in future exams.
Notably, all firms should perform a self-assessment of their trading strategies in light of the Final Rules. While firms that meet the criteria used by the SEC may want to engage in more comprehensive self-assessments, the deficiencies in the SEC’s estimates mean that other firms should not assume they are outside the scope of the Final Rules.
Issues for Advisers and Funds That Register
Dealers are subject to a number of rules and requirements to which registered investment advisers, private funds and principal trading firms are not currently subject. While the scope of the Final Rules have generally been narrowed, given the ambiguity in the Final Rules, we highlight certain considerations relating to dealer registration.
SRO Membership
A dealer must register with one or more self-regulatory organizations (“SROs”), and most dealers are required to become members of FINRA.[43] SRO members are subject to the relevant SRO’s rules, including a number of technical rule requirements that are not applicable to other market participants (e.g., consolidated audit trail and trade reporting obligations), and periodic examinations by the SRO.
New Issues (IPO) Restrictions
FINRA Rules 5130 and 5131 (commonly known as the FINRA “new issues” rules) restrict certain market participants from receiving shares in initial public offerings (“IPOs”), including broker-dealers, associated persons of a broker-dealer and certain persons owning a broker-dealer. If a private fund is registered as a dealer, the fund would be restricted from receiving shares in an IPO and, relatedly, certain of its owners (e.g., its limited partners) could similarly become restricted from participating.[44]
Capital Withdrawals
Dealers are subject to the net capital requirements of Exchange Act Rule 15c3-1 (the “Net Capital Rule”). Generally, the Net Capital Rule requires that dealers maintain more than a dollar of highly liquid assets for each dollar of liabilities. The Net Capital Rule highly discourages withdrawals of capital within one year of contribution, providing, generally, that any capital withdrawn within one year of contribution was never eligible to be treated as “good” capital for purposes of the Net Capital Rule. If a private fund (or its subsidiary) registers as a dealer, the private fund’s existing liquidity terms may need to be amended in order to include all of the investors’ capital as “good” capital and any such amendment is likely to require investor consent.
Change in Control Filings
FINRA rule 1017 requires that broker-dealers file an application for any change in ownership that results in one person or entity directly or indirectly owning or controlling 25 percent or more of the equity or partnership capital. While, in certain cases, closing may occur thirty (30) days after filing of such application, FINRA may impose interim restrictions that delay closing until 180 days (or longer) after filing. This could delay a private fund’s ability to accept new subscriptions or process redemptions to the extent such subscriptions or redemptions require a filing of a “change in ownership” application by such private fund or its subsidiary.
Other Considerations
- Certain investors may not be permitted to invest (directly or indirectly) in the equity of a broker-dealer and may need to be redeemed from the private fund before the private fund or its subsidiary becomes a registered dealer.
- Modifying a fund’s investment strategy (e.g., by moving the dealer activity out of the private fund to a new entity that is not owned by the private fund to avoid dealer registration at (or below) the private fund level) may require investor consent and also trigger investor redemption rights.
Compliance Deadline
The final rules will become effective 60 days following the date of publication of the Adopting Release in the Federal Register. The compliance date will be one year after the effective date of the Final Rules (“Compliance Period”) and, in a departure from the Proposal, the Compliance Period applies to both market participants engaged in activity that meets one or both adopted tests prior to the effective date and new entrants.
Impacted persons will need to have their dealer registrations approved by the end of the Compliance Period (absent an extension). This represents a very short window as impacted firms will need to identify, among other things, the anticipated ownership structure, personnel and procedures. Further, while FINRA indicated it would attempt to expedite the registration process for entities impacted by the Final Rules, in our experience FINRA approval of a new membership application can easily take over six (6) months from the date of submission.
Authored by William J. Barbera, Jennifer M. Dunn, Marc E. Elovitz, Kelly Koscuiszka, Julian Rainero, Derek N. Lacarrubba, and Kristopher J. Kendall.
If you have any questions concerning this Client Alert, please contact your attorney or one of the authors.

New York 1115 Waiver Amendment Timeline for Medicaid Hospital Global Budget Initiative
ARTICLE / CLIENT ALERT
New York 1115 Waiver Amendment Timeline for Medicaid Hospital Global Budget Initiative
February 20, 2024
Read time: 2 min
The New York Medicaid 1115 Waiver amendment introduces the Medicaid Hospital Global Budget Initiative (GBI), closely aligned with the States Advancing All-Payer Health Equity Approaches and Development (AHEAD) model.
The New York waiver aims to provide financial stability to certain downstate hospitals serving a high percentage of Medicaid beneficiaries, while driving delivery reform for accountability and health equity. The GBI functions by providing hospitals with a global revenue budget for specific services, ensuring a certain amount of revenue and, in theory, providing a degree of financial stability. In addition, participating hospitals will receive financial support over the next three years, aggregating to approximately $2.2 billion, if requirements are met.
This article summarizes these requirements for the state and the participating hospitals. For more information or for assistance with compliance, please contact Katie Waldo or Dale C. Van Demark.

CMS Releases Guidance on Coverage Criteria, Utilization Management and Use of AI
ARTICLE / CLIENT ALERT
CMS Releases Guidance on Coverage Criteria, Utilization Management and Use of AI
February 20, 2024
Read time: 6 min
On February 6, 2024, the US Centers for Medicare & Medicaid Services (CMS) released a set of frequently asked questions (FAQs) related to Medicare Advantage (MA) coverage criteria and utilization management (UM) requirements. The FAQs provide guidance on new regulatory requirements regarding the use of internal coverage criteria for basic benefits, prior authorization, UM tools and more, which were outlined in an April 2023 final rule and went into effect for coverage beginning on January 1, 2024.
Use of AI in Coverage Determinations
Stakeholders have raised questions concerning the role of artificial intelligence (AI), algorithms and similar tools in making coverage determinations. This discussion has attracted more attention as new technologies emerge and expand across the industry. In addition, several health insurers are now facing class action litigation regarding their alleged use of AI models or algorithms in the review and denial of medical claims.
In the preamble to the final rule, CMS stated that Medicare Advantage Organizations (MAOs) must make medical necessity determinations based on the circumstances of specific individuals, as opposed to relying on an algorithm or software that does not consider individual circumstances. In the FAQs, CMS clarifies that an algorithm or software tool can be used to assist MAOs in making coverage determinations, provided that such tools comply with all applicable coverage determination rules. CMS reasons that “an algorithm that determines coverage based on a larger data set instead of the individual patient’s medical history, the physician’s recommendations, or clinical notes would not [emphasis added] be compliant[.]” CMS specifically notes that algorithms and AI cannot be used to solely deny certain care; in particular:
- An algorithm or software tool predicting the length of a patient’s post-acute care stay cannot be the sole grounds for terminating services.
- An algorithm or AI cannot be used to solely deny an inpatient admission or downgrade to an observation stay.
In each case, the patient’s unique circumstances and present condition must be considered.
CMS also cautions that algorithms and software tools used to deny coverage for basic benefits cannot incorporate coverage criteria beyond that allowed by CMS regulations. Finally, CMS expresses concerns that algorithms and AI technologies can “exacerbate discrimination and bias,” suggesting that MAOs must take care to ensure that their use does not violate the nondiscrimination provisions of Section 1557 of the Affordable Care Act.
Internal Coverage Criteria: Public Accessibility, Current Evidence and More
The final rule provided that when Medicare coverage criteria are not fully established, MAOs may develop internal coverage criteria for making determinations; however, that criteria must be based on current evidence in “widely used treatment guidelines” or “clinical literature” and must be made “publicly accessible.” (See 42 CFR 422.101(b)(6).) The FAQs elaborate on these requirements for internal coverage criteria, as follows:
- Publicly accessible. Per the FAQs, “publicly accessible” means that:
- The criteria must be accessible via a website (including the MAO’s website or a delegated vendor’s website) and not behind a paywall or subscription.
- The criteria must be accessible to all members of the public and not limited to enrollees and contracted providers.
- The MAO can require an individual to provide one or two pieces of basic information to access the criteria.
- Providing multiple links to vendor’s websites may present such a large burden as to render the criteria not publicly accessible.
- Clinical benefits outweighing clinical harms. The final rule states that when additional criteria are needed to interpret general provisions, MAOs must demonstrate how the additional criteria provide clinical benefits that are highly likely to outweigh any clinical harms. In the FAQs, CMS adds that it expects MAOs to publicly and systematically explain the clinical benefits of the criteria compared to the harms patients may experience. An explanation that merely assumes that coverage criteria generally offer clinical benefits is insufficient. “[A]ll internal coverage criteria should clearly and explicitly support patient safety before the criteria are used[.]” CMS will monitor the rationales that are made public.
- Local coverage determinations. The FAQs explain that if the Local Coverage Determination (LCD) is not from the applicable service area, reliance on the LCD is considered use of internal coverage criteria. The MAO may use such criteria but must ensure that is it still based on current evidence in widely used treatment guidelines or clinical literature.
Other Issues
Beyond internal coverage criteria, CMS’s FAQs provide guidance on other topics related to the final rule, including:
- Post-service reviews: CMS reiterates its position that post-service reviews that result in a denial of coverage, in whole or in part, are organization determinations – not “payment” reviews. This means that such reviews must be consistent with the reopening rules and CMS regulations prohibiting MAOs from denying coverage for services already subject to a prior authorization on the basis of lack of medical necessity. Notably, CMS concludes the discussion by focusing on adverse decisions “about whether the services are or were medically necessary,” thus suggesting a potential distinction between post-service reviews that result in organization determinations and those that can be classified as payment reviews.
- Prior authorization and skilled nursing facilities (SNFs): CMS clarifies in one FAQ that the new rules requiring that an approval of a prior authorization request for a course of treatment be valid for as long as medically necessary extend to an interrupted stay in an SNF. CMS notes that a new prior authorization approval is not required for admission when the patient returns no more than three consecutive days after being discharged.
CMS Enforcement in 2024
CMS announced previously that it would conduct routine and focused program audits in 2024 to assess organizations’ compliance with the new coverage criteria and UM rules. For those who have routine program audits scheduled for 2024, CMS will assess the new requirements during the Part C Organization Determinations, Appeals, and Grievances (ODAG) review and Compliance Program Effectiveness (CPE) review. For those who do not have audits scheduled, CMS will add focused audits specifically targeting the final rule requirements. These focused audits will be limited to ODAG and CPE.
CMS expects to evaluate the UM practices of plans serving nearly 90% of enrollees with MA. CMS may address noncompliance through a variety of compliance and enforcement actions, including issuing notices of noncompliance, warning letters, corrective action plans, and/or imposing civil money penalties and enrollment or marketing sanctions.

The MHPAEA proposed rule: ‘Meaningful benefits’ and the ‘scope of services’
ARTICLE
The MHPAEA proposed rule: ‘Meaningful benefits’ and the ‘scope of services’
February 20, 2024
Read time: 8 min
This post continues our consideration of comments submitted in response to proposed regulations under the Mental Health Parity and Addiction Equity Act (MHPAEA).
Under current law, if a plan provides any mental health or substance use disorder (MH/SUD) benefits in any classification of benefits, benefits for that condition or use disorder must be provided in every classification in which medical/surgical (M/S) benefits are provided. Classifications for this purpose include inpatient, in-network; inpatient, out-of-network; outpatient, in-network; outpatient, out-of-network; emergency care; and prescription drugs. The proposed regulations modify this standard by providing that a plan does not provide benefits for MH/SUD benefits in every classification in which M/S benefits are provided unless the plan provides meaningful benefits for treatment for the condition or disorder in each such classification “as determined in comparison to the benefits provided for medical/surgical conditions in the classification.”
The term “meaningful benefits” is nowhere defined. The regulators nevertheless “recognize that the proposal to require meaningful benefits [ ] is related to scope of services.” “Scope of services” for this purpose generally refers to the types of treatments and treatment settings that are covered by a group health plan or health insurance issuer. The preamble to the proposed regulation invites comments on how the meaningful benefits requirement “would interact with the approach related to scope of services adopted under the 2013 final regulations.” The preamble of the 2013 final regulations addressed an issue characterized as ‘‘scope of services’’ or ‘‘continuum of care’’ but otherwise failed to provide any substance. Two examples from the proposed regulations do, however, give us a sense of what the regulators have in mind.
- A plan that generally covers treatment for autism spectrum disorder (ASD), a mental health condition, and covers outpatient, out-of-network developmental evaluations for ASD but excludes all other benefits for outpatient treatment for ASD, including applied behavior analysis (ABA) therapy, when provided on an out-of-network basis. (ABA therapy is one of the primary treatments for ASD in children.) The plan generally covers the full range of outpatient treatments and treatment settings for M/S conditions and procedures when provided on an out-of-network basis. The plan in this example violates the applicable parity standards.
- In another example, a plan generally covers diagnosis and treatment for eating disorders, a mental health condition, but specifically excludes coverage for nutrition counseling to treat eating disorders, including in the outpatient, in-network classification. Nutrition counseling is one of the primary treatments for eating disorders. The plan generally provides benefits for the primary treatments for medical conditions and surgical procedures in the outpatient, in-network classification. The exclusion of coverage for nutrition counseling for eating disorders results in the plan failing to provide meaningful benefits for the treatment of eating disorders in the outpatient, in-network classification, as determined in comparison to the benefits provided for M/S conditions in the classification. Therefore, the plan violates the proposed rules.
Notably, the newly proposed meaningful benefits requirement is separate from, and in addition to, the newly prescribed nonquantitative treatment limitation (NQTL) testing standards. These latter standards include a “no more restrictive” requirement, a “design and application” requirement and an “outcomes data and network composition” requirement. A handful of comments nevertheless urge the regulators to add scope of services to its non-exhaustive list of NQTLs. As a result, a plan’s scope of services would be subject to comprehensive NQTL testing. Or, put another way, they would be fed back into the NQTL testing loop. Using the first of the examples above, this would require that ABA therapy to be first compared to the treatment limitations imposed on some M/S benefits in each classification. But what benefits, exactly? The problem is that a plan’s scope of services – what types of treatments a plan will pay for and in what settings – is a high-level plan design feature and not an NQTL.
While reasonable minds can and do differ on much of the substance of the proposed regulations, we doubt that anyone would claim that they streamline or simplify compliance. Compliance with these rules is already complicated and expensive; if the final rule looks anything like the proposed regulations, compliance will only get more complicated and more expensive. The proposed meaningful benefits requirement is intended to prevent plans, as a matter of plan design, from satisfying the parity rules by offering nominal or insubstantial MH/SUD benefits when compared to similar M/S benefits in each classification. Treating a plan’s scope of services as itself a separate NQTL does not advance this goal.

Pending Oregon Law Undermines Traditional Physician Practice Structure
ARTICLE / CLIENT ALERT
Pending Oregon Law Undermines Traditional Physician Practice Structure
February 16, 2024
Read time: 7 min
In an apparent attempt to shield physician practices from perceived abuses of close association with physician practice management (PPM) companies, a pending Oregon law could undermine a broad range of structures and transactions between physicians and laypersons. Potentially affected structures and transactions include loans, real estate leases, practice non-clinical asset sales, national virtual care platforms and payor-provider joint ventures.
While the pending legislation continues to evolve (including recent amendments that would exclude many exclusively virtual care models from its more onerous restrictions and prohibitions), its basic contours seem to remain the same. The legislation’s effect could transform Oregon’s physician practice community into a classic “cottage industry,” isolated from the impact of modern management, administrative and financial practices, and – if the virtual care exceptions do not remain or ultimately do not apply broadly – strip Oregonians of the opportunity to use the services of the vast majority of virtual care platforms.
About the Law
Oregon House Bill 4130 (the Act) is a comprehensive bill that includes specific restrictions related to domestic and foreign professional entities and enforcement mechanisms. Primarily, the Act prohibits several relationships and control structures, which would materially constrain the typical PPM structure utilized by hospitals, private equity sponsors, virtual care providers, managed care companies and others to create a more integrated approach to care delivery, to take advantage of efficiencies and, in many instances, simply to operate. As of now, the Act excludes hospitals, physician-majority owned management service organization structures and practices that provide telemedicine without a physical presence in the state, among others. We expect the provisions to continue to evolve.
PPM structures, at their core, are ways to create business stability across multiple practices. Without this stability, sophisticated management companies may be wary about making significant investment in certain practices. In some instances, such as in virtual practices, which often rely on complex technological prowess developed by lay entities and are married with quality clinical care, there would be very little ability to execute on the organization’s mission.
The Act’s Limitations
The Act’s restrictions are broadly crafted to limit the various levers of alignment that physicians and management companies have traditionally deployed. Importantly, the limitations apply across a broad spectrum of practices, such as those that include different types of licensed professionals practicing together, and organizational structures, including limited liability companies (all of which are referred to as “professional corporations” in this article). Specifically, the Act provides the following restrictions and limitations:
- Limitation on Agreements for Control. The Act prohibits any professional corporation from relinquishing control over its “assets, business operations, clinical practices or decisions or the clinical practices or decisions of a physician. . .” The Act broadly describes methods by which this restriction might otherwise be accomplished:
- Selling, issuing or restricting transfers of shares
- Entering noncompetition, nondisclosure or non-disparagement agreements (as otherwise described in the Act)
- Determining employment matters (e.g., hiring and firing, setting compensation and staffing levels)
- Entering third-party contracts (including payor arrangements)
- Controlling diagnostic coding decisions and establishing billing and collection policies
- Limiting physician access to physician rates or charges
While many of these limitations are features of current PPM structures, such as the restrictions on a management services company influencing clinical decisions, others are common features of PPM structures designed to ensure a long-term relationship and place control over non-clinical administrative functions in the hands of management services organizations. Absent these features, many of the large medical organizations currently serving Oregon’s population may be forced to either cease operations within the state or divest all holdings. Additionally, as restrictions on the transference of shares or the sale of assets are common covenants included in credit agreements, these limitations would (perhaps unintentionally) hinder the ability of Oregon physician practices to utilize secured debt.
Significantly, this limitation does not apply to telemedicine practices with no physical location within the state, Program of All-Inclusive Care for the Elderly (PACE) organizations, hospital affiliates or licensed behavioral health services providers. Additionally, a majority of Oregon licensed clinicians can provide for such control provisions via a shareholder agreement for the benefit of many shareholders who are licensed clinicians.
- Cross-Ownership Management Limitation. The Act prohibits any shareholder, director, or officer of a professional corporation from owning shares; being a director, officer, employee, or independent contractor; or participating in the management of a management services organization under contract with the professional corporation. The Act also prohibits a “back door” by further prohibiting shareholders of professional corporations who are also shareholders, directors, members, officers or employees of the associated management company from granting a proxy to vote their shares.
The same exclusions apply here (other than the proxy provisions) as for the above.
- Removal Limitation. The Act requires at least a majority of shareholders and directors and all officers (other than the secretary and treasurer) to be Oregon licensed physicians and prohibits the removal of any director or officer except by such licensed practitioners (with some exceptions for bad actors).
- Noncompetition Limitation. The Act makes any noncompetition agreement that prohibits an Oregon licensed physician from providing “products, processes or services” that are similar to those offered by the counterparty void. This prohibition is not applicable when a clinician sells their practice or when the clinician has an ownership interest in the counterparty.
- Nondisclosure and Non-Disparagement Limitation. The Act makes any nondisclosure or non-disparagement agreement between an Oregon licensed physician and a management services organization unenforceable. Both nondisclosure and non-disparagement agreements are simply defined, but the definitions are quite broad:
- A non-disparagement agreement prohibits a licensed physician from making a statement that “causes or threatens to cause harm to the other party’s or person’s reputation, business relations or other economic interests.”
- A nondisclosure agreement prohibits a licensed physician from disclosing:
- A policy, practice, process or technique that the licensed physician was required to use in patient care
- A policy, practice, process or other information regarding the licensed physician’s employment, including compensation amounts or rates
- Any other information that the licensed physician had access to by virtue of their employment or other relationship with the counterparty.
In addition to prohibiting the effectiveness of these agreements, the Act also prohibits the counterparty from taking other retaliatory action against the licensed physician for breaches of these agreements.
- Potentially Expansive Reach. The Act defines “management services organizations” to include any entity that provides, pursuant to a written agreement for compensation, any administrative or business service that does not constitute the practice of medicine, including (but not limited) to payroll support, human resources, employee screening or employee relations. Accordingly, the Act captures a broad host or arrangements that physicians may wish to establish without the involvement of financial sponsors, including physician investment in vendors providing services to any practice in which they own or providing medical services.
Additional Provisions
The Act empowers the US secretary of state to investigate any complaint from the Oregon Health Authority or any other person about a violation of these restrictions and may administratively dissolve or revoke the foreign qualification of offending organizations. Additionally, the Oregon Health Authority may refer to the US attorney general any merger or acquisition that it believes violates these provisions. The attorney general may then prohibit the transaction or enter a settlement agreement to permit the transaction.
The Act includes additional provisions around professional corporation ownership reporting and nurse practitioner employment limitations, among others, but the core of the Act’s impact is in the restrictions enumerated above.
While the Act is still in development, it is difficult to see a passage of even a highly modified version, which would not have a significant impact on PPM structures within Oregon.

Shares Acquired Upon the Exercise of BSPCEs Now Eligible for Tax Neutrality Regime in Share-for-Share Contribution Cases
ARTICLE / CLIENT ALERT
Shares Acquired Upon the Exercise of BSPCEs Now Eligible for Tax Neutrality Regime in Share-for-Share Contribution Cases
February 15, 2024
Read time: 4 min
On February 5, 2024, the French Supreme Tax Court (Conseil d’État) voided French tax authority guidelines from May 2023 that provided that shares acquired upon the exercise of founder stock options, or Bons de Souscription de Parts de Créateur d’Entreprise (BSPCEs), could not benefit from the tax neutrality regime provided for in Article 150-0 B of the French Tax Code in the case of share-for-share contributions to a company.*
Read the full client alert, “Le sursis d’imposition s’applique à l’apport de titres acquis en exercice de BSPCE,” in French.
BSPCEs enable eligible companies to grant their employees and managers the right to subscribe shares at a predetermined price. Created to encourage profit-sharing, BSPCEs are subject to an attractive tax and social security regime. The issuing company is exempt from French social security contributions once BSPCEs are granted and exercised. The holder is subject to French capital gains taxation on the gain arising from the disposal of the subscribed shares upon the exercise of the BSPCEs at the aggregate rate of 30% or 47.2% – depending on whether the holder has been employed by the issuing company (or a subsidiary) for more or less than three years at the time of disposal.
Article 163 bis G of the French Tax Code governs the taxation of BSPCEs and references the standard capital gain regime to define the rules applicable to gains that are derived from the disposals of shares acquired upon the exercise of BSPCEs. Based on both a literal interpretation of this article as well as on the parliamentary work leading up to the introduction of BSPCEs into French law, the French Supreme Tax Court voided the French tax authority’s guidelines and held that “the legislator intended to subject the net gain realized upon the sale of shares subscribed upon exercise of BSPCEs to the standard regime applicable to capital gains set out in articles 150-0 A et seq. of the same code, subject only to the specific rules regarding rates that it provides.” This is particularly the case for contributions to a company that are not controlled by the contributor of subscribed shares in the exercise of such warrants, where the contributor benefits from the standard tax neutrality regime provided for in Article 150-0 B.
This decision will significantly impact reinvestments made by BSPCE holders, confirming that any such reinvestment effected through a share-for-share contribution will not give rise to a French dry tax charge. This decision is particularly significant for holders who are compelled to exercise their BPSCEs and roll over their shares because of a liquidity event occurring less than three years after joining the company and would have previously been subject to French income tax on the unrealized gain at the unfavorable rate of 47.2% had the French tax authority’s guidelines been upheld.
This decision also affects the tax deferral mechanism provided for under Article 150-0 B ter, which applies to share-for-share contributions to a company controlled by the contributor. The tax rate applicable to the deferred gain would definitively crystallize (at 30% or 47.2%) depending on the tenure of the contributor at the time of the contribution.
*Joseph Righenzi (trainee) contributed to this article
